The cataract surgery population is growing, and patients are presenting with vision needs that differ from those of previous generations. New IOL technology, including aspheric, multifocal, and accommodating designs, is helping surgeons meet the changing paradigm in patient expectations.
Results of a multicenter FDA clinical trial of a fourth-generation version of an accommodating IOL (crystalens HD-100, eyeonics/Bausch & Lomb) demonstrate that the lens provides excellent uncorrected visual acuity at all distances that exceeds those of previous versions and without causing loss of contrast sensitivity.
Calculating corneal spherical aberration-especially in eyes with extreme ranges of corneal spherical wavefront aberrations-by using the recorder function of a diagnostic system with analytical software may be beneficial when choosing an IOL that has positive, neutral, or negative SA to reduce postoperative SA in the whole eye.
Cary Rayment, who was honored Jan. 23 by the Glaucoma Research Foundation (GRF) with the 2008 GRF Catalyst Award, is leading his company's strategic plan to spend more than $3.5 billion on research over the next 5 years.
Women remain underrepresented at the higher levels of academic medicine and in executive positions, but these trends are certain to change as the female physicians now starting their careers accumulate experience.
Cataract surgeons agree that proper incision construction is paramount for achieving good postoperative stability that will reduce the risk for endophthalmitis. The safety of the clear cornea incision technique versus use of other incision types remains controversial, however.
Women remain underrepresented at the higher levels of academic medicine and in executive positions, but these trends are certain to change as the female physicians now starting their careers accumulate experience.
Femtosecond laser (IntraLase, Advanced Medical Optics) technology is capable of performing nonmechanical dissection of the posterior lamellar disc for endothelial keratoplasty in a safe manner.
Patients with age-related macular degeneration have twice the risk of dying from heart attack or stroke, according to Australian researchers.
Cataract surgery incision sizes have been significantly reduced by new technology. Now surgeons can make two 1.8-mm cuts on either side of the eye.
Epinastine HCl 0.05% does not have a drying effect on the ocular surface and may be kinder to patients being treated for seasonal allergies and underlying dry eye disease.
The origin of the term glaucoma is disputed. Its meaning through antiquity is also poorly understood. Today there are an increasing number of medications. But as yet we are still in the Dark Ages insofar as the cause of this visually disabling disorder.
The ARVO meeting will feature more than a dozen minisymposia by the ARVO sections, education courses, workshops, special interest group sessions, and events aimed specifically at members-in-training.
Preoperative donor endothelial cell count does not affect the rate of dislocation in endothelial keratoplasty. The surgical technique is likely the most important factor that drives the dislocation rate, primary graft failure rate, and long-term endothelial survival, according to one surgeon.
An interim analysis of a dose-escalation phase I trial of sirolimus for the treatment of diabetic macular edema has found promising efficacy signals and no safety concerns.
Phakic IOL implantation has advantages as a method of refractive surgery. Enhancement may be needed to optimize the refractive result, but many issues should be considered before undertaking an enhancement and when offering this technology to potential candidates.
Surgically induced refractive errors can compromise vision following penetrating keratoplasty. Considerations for evaluation and management of patients needing an enhancement are discussed.
LASIK in 2007 represents a wonderful world that can provide excellent efficacy, safety, and stability. Multiple innovations are the foundation for today's improved outcomes, and the outlook is bright for future advances.
Results of a pivotal phase III trial of a cyclosporine A product for the treatment of vernal conjunctivitis (VKC) in children showed that the drug improved symptoms and signs of the orphan disease, and tolerability was excellent, according to the manufacturer.
A pooled analysis of three randomized, double-masked, placebo-controlled, conjunctival allergen challenge trials demonstrates that once-daily treatment with olopatadine 0.2% (Pataday, Alcon Laboratories) is equally effective for improving ocular itching caused by exposure to indoor or outdoor allergens.
Epinastine HCl 0.05% does not have a drying effect on the ocular surface and may be kinder to patients being treated for seasonal allergies and underlying dry eye disease.
To treat the ocular discomfort associated with allergic conjunctivitis several medications are in the pipeline.
Medical technology company Optos is collaborating with Eyemaginations to produce animations designed to enable eye-care professionals to educate their patients about diabetic retinopathy, retinal detachment, glaucoma, and choroidal nevi.
Fortune magazine has named Genentech and Alcon Laboratories to its latest "100 Best Companies to Work For" list.
The Wilmer Ophthalmological Institute is celebrating the 25th anniversary of its Current Concepts in Ophthalmology meeting in Vail, CO, this year.
Progress in the diagnosis and treatment of retinoblastoma has been minimal over the past couple of decades, although improvements have been made, and new therapies are being studied, according to an ocular oncology expert.
The eye has played an important role in angiogenesis research over the past several decades, and it will continue to do so, according to Judah Folkman, MD, considered the founder of the field.
Judah Folkman, MD, whose work in cancer research led to significant breakthroughs in treating age-related macular degeneration, is being remembered as the kindly and compassionate "father of angiogenesis."
Bausch & Lomb. acquired IOL manufacturer eyeonics, announced a new research deal, and gained a new chairman and chief executive officer.
Post-occlusion surge varies from phacoemulsification system to system based on several different parameters, including decreasing flow, increasing bottle height, decreasing tip gauge, and flow restriction. Randall J. Olson, MD, details recent research.
